IP Library › Granted Patent US 9,687,499
Granted Patent B2
US 9,687,499 · App. 14/749,091 · Granted Jun 27, 2017

Method using heat shock protein inhibitor for treating hepatitis and hepatoma

Inventors: Hui-Ching Wang (Hsinchu, TW); Ting-Chung Yen (Hsinchu, TW); Li-Rung Huang (Hsinchu, TW)
A61K31/7076A61K31/18A61K31/706A61K31/7064
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,687,499
App. No.
14/749,091
Granted
Jun 27, 2017
Kind
B2
Abstract

The present invention is directed to a use of a heat shock protein inhibitor in preparing pharmaceutical composition for treating hepatitis by scavenging hepatitis B virus-infected cells. The heat shock protein inhibitor is selected from a group including VER-155008, Pifithrin-μ, and pharmaceutical acceptable salts thereof. The present invention is also directed to a use of a heat shock protein inhibitor in preparing pharmaceutical composition for treating hepatoma.

Claims (12)

1. A method for treating hepatitis B, which comprises administering an effective amount of the pharmaceutical composition to a subject infected hepatitis with B virus;

wherein the pharmaceutical composition comprises: 5′-O-[(4-Cyanophenyl)methyl]-8-[[(3,4-dichlorophenyl)methyl]amino]-adenosine (VER-155008), 2-Phenylethynesulfonamide (Pifithrin-μ), or pharmaceutical acceptable salts thereof.

2. The method for treating hepatitis B according to claim 1 , wherein said heat shock protein inhibitor is selected from a group consisting of VER-155008 and Pifithrin-μ.

3. The method for treating hepatitis B according to claim 1 , wherein said heat shock protein inhibitor is VER-155008.

4. The method for treating hepatitis B according to claim 1 , wherein said heat shock protein inhibitor is Pifithrin-μ.

5. The method for treating hepatitis B according to claim 1 , wherein said pharmaceutical composition further comprises a pharmaceutical carrier.

6. A method for treating hepatoma, which comprises administering an effective amount of the pharmaceutical composition to a subject afflicted with hepatoma:

wherein the pharmaceutical composition comprises 5′-O-[(4-Cyanophenyl)methyl]-8-[[(3,4-dichlorophenyl)methyl]amino]-adenosine (VER-155008), 2-Phenylethynesulfonamide (Pifithrin-μ), or pharmaceutical acceptable salts thereof.

7. The method for treating hepatoma according to claim 6 , wherein said heat shock protein inhibitor is selected from a group consisting of VER-155008 and Pifithrin-μ.

8. The method for treating hepatoma according to claim 6 , wherein said heat shock protein inhibitor is VER-155008.

9. The method for treating hepatoma according to claim 6 , wherein said heat shock protein inhibitor is Pifithrin-μ.

10. The method for treating hepatoma according to claim 6 , wherein said hepatoma is caused by hepatitis B virus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2015
From: WANG, HUI-CHING; YEN, TING-CHUNG; HUANG, LI-RUNG
To: NATIONAL TSING HUA UNIVERSITY
Reel/Frame 036527/0988 →
Priority Claims (1)
TW 103121657 A · Jun 24, 2014 · national
Continuity (1)
Related Publication 20150366892A1 · Dec 24, 2015